Multiple sclerosis is an acquired, chronic, immune-mediated, inflammatory disease of the brain and the spinal cord characterized by the presence of multiple discrete areas of myelin loss within the CNS and subsequent axonal degeneration.
It affects more women than men; however, men are more likely to have a malignant clinical course.
A multiple sclerosis attack is usually characterized by any neurological disturbance with minimum 24 hours duration in the absence of fever or infection.
In patients with relapsing-remitting multiple sclerosis (MS), certain disease-modifying therapies (DMTs) may be more associated with serious infections than others, according to an observational study from Sweden.
New drug applications approved by US FDA as of 16 - 30 September 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Use of both ipratropium and salmeterol is associated with reduced likelihood of being diagnosed with multiple sclerosis, according to a study, suggesting that the drugs may help prevent or stop the development of the disease in its early stages.
Daily use of the selective oral Bruton’s tyrosine kinase inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.
The oral BTK* inhibitor evobrutinib at a dose of 75 mg/day reduced the number of gadolinium-enhancing lesions in patients with relapsing multiple sclerosis (MS), according to a phase II trial presented at AAN 2019.
Early treatment with currently available immunotherapeutic agents can delay the progression of disability and confer long-term benefits for patients with relapsing-remitting multiple sclerosis (RRMS), an international study finds.
Low levels of sun exposure throughout childhood appears to be associated with an increased risk of developing multiple sclerosis in adulthood, a study reports. Notably, the risk is greatest in those who spend most time indoors and use sun protection frequently in their limited time outdoors.
Fingolimod was superior to the standard of care, interferon beta-1a, in reducing relapses and lesion accumulation in children and adolescents with multiple sclerosis (MS) over 2 years, although the treatment was associated with more serious adverse events than the comparator, according to the landmark PARADIGMS study, which forms the basis for the recent expansion of FDA’s approval of this drug to include children and adolescents.
A 38-year-old right-handed man had had epilepsy since 2 months of age. There was no relevant family history. Perinatal history was unremarkable. No other risk factors such as central nervous system infection or cerebral trauma were identified. Developmental history did not show major delay. His epilepsy was uncontrolled despite trying valproate, carbamazepine, clobazam, levetiracetam, oxcarbamazepine and perampanel.